GB0011903D0
(en)
*
|
2000-05-18 |
2000-07-05 |
Astrazeneca Ab |
Combination chemotherapy
|
US8580782B2
(en)
*
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US8242254B2
(en)
|
2003-09-11 |
2012-08-14 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
US8546082B2
(en)
*
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US20080138808A1
(en)
*
|
2003-09-11 |
2008-06-12 |
Hall Thomas A |
Methods for identification of sepsis-causing bacteria
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
WO2005049593A2
(en)
*
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
US7973161B2
(en)
*
|
2003-11-13 |
2011-07-05 |
Abbott Laboratories |
Apoptosis promoters
|
US7767684B2
(en)
*
|
2003-11-13 |
2010-08-03 |
Abbott Laboratories |
Apoptosis promoters
|
US8614318B2
(en)
*
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
TWI337608B
(en)
*
|
2005-05-12 |
2011-02-21 |
Abbott Lab |
Apoptosis promoters
|
US8624027B2
(en)
*
|
2005-05-12 |
2014-01-07 |
Abbvie Inc. |
Combination therapy for treating cancer and diagnostic assays for use therein
|
US20080160545A1
(en)
*
|
2006-09-05 |
2008-07-03 |
Abbott Laboratories |
Pro-GRP as a surrogate marker to predict and monitor response to Bcl-2 inhibitor therapy
|
JP5277168B2
(ja)
*
|
2006-09-05 |
2013-08-28 |
アボット・ラボラトリーズ |
血小板過剰を治療するbclインヒビター
|
US8168661B2
(en)
*
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8173686B2
(en)
|
2006-11-06 |
2012-05-08 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8168662B1
(en)
|
2006-11-06 |
2012-05-01 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8178564B2
(en)
*
|
2006-11-06 |
2012-05-15 |
Poniard Pharmaceuticals, Inc. |
Use of picoplatin to treat colorectal cancer
|
US8168645B2
(en)
*
|
2006-11-15 |
2012-05-01 |
Genentech, Inc. |
Arylsulfonamide compounds
|
WO2008064116A2
(en)
*
|
2006-11-16 |
2008-05-29 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
US20100087436A1
(en)
*
|
2006-11-16 |
2010-04-08 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
US20100260832A1
(en)
*
|
2007-06-27 |
2010-10-14 |
Poniard Pharmaceuticals, Inc. |
Combination therapy for ovarian cancer
|
US20100310661A1
(en)
*
|
2007-07-16 |
2010-12-09 |
Poniard Pharmaceuticals, Inc. |
Oral formulations for picoplatin
|
US20090098118A1
(en)
*
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
RU2526201C2
(ru)
*
|
2007-11-16 |
2014-08-20 |
Эббви Инк. |
Способ лечения артрита
|
CA2708223A1
(en)
*
|
2007-12-06 |
2009-06-11 |
Andrew Krivoshik |
Oral compositions of abt-263 for treating cancer
|
WO2009085216A2
(en)
|
2007-12-20 |
2009-07-09 |
Squicor |
Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
|
CN101220008B
(zh)
*
|
2008-01-21 |
2011-04-27 |
中国科学院广州生物医药与健康研究院 |
化合物abt-263的合成方法
|
EP2244714A4
(en)
*
|
2008-02-08 |
2012-06-06 |
Poniard Pharmaceuticals Inc |
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
|
ES2378754T3
(es)
*
|
2008-06-09 |
2012-04-17 |
Bristol-Myers Squibb Company |
Hidroxifenilsulfonamidas como inhibidores de Bcl antiapoptóticos
|
US8168784B2
(en)
*
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
UA108193C2
(uk)
*
|
2008-12-04 |
2015-04-10 |
|
Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
|
US8557983B2
(en)
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8586754B2
(en)
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
ES2588374T3
(es)
*
|
2008-12-05 |
2016-11-02 |
Abbvie Inc. |
Derivados de sulfonamidas como agentes inductores de la apoptosis selectivos para bcl-2 para el tratamiento del cáncer y enfermedades inmunitarias
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
CA2747185A1
(en)
|
2008-12-08 |
2010-06-17 |
Boehringer Ingelheim International Gmbh |
Compounds for treating cancer
|
CA2747837A1
(en)
|
2009-01-19 |
2010-07-22 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
SI2511264T1
(sl)
*
|
2009-01-19 |
2015-07-31 |
Abb Vie Inc. |
Sredstva za induciranje apoptoze za zdravljenje raka ter imunskih in avtoimunskih obolenj
|
US20100280031A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Paul David |
Lipid formulation of apoptosis promoter
|
US8362013B2
(en)
*
|
2009-04-30 |
2013-01-29 |
Abbvie Inc. |
Salt of ABT-263 and solid-state forms thereof
|
US8728516B2
(en)
*
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
US20100278921A1
(en)
|
2009-04-30 |
2010-11-04 |
Fischer Cristina M |
Solid oral formulation of abt-263
|
US20100297194A1
(en)
*
|
2009-04-30 |
2010-11-25 |
Nathaniel Catron |
Formulation for oral administration of apoptosis promoter
|
US9034875B2
(en)
|
2009-05-26 |
2015-05-19 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20220315555A1
(en)
|
2009-05-26 |
2022-10-06 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
KR20190086591A
(ko)
*
|
2009-05-26 |
2019-07-22 |
애브비 아일랜드 언리미티드 컴퍼니 |
암,면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
|
TWI540132B
(zh)
*
|
2009-06-08 |
2016-07-01 |
亞培公司 |
Bcl-2族群抑制劑之口服醫藥劑型
|
TWI532484B
(zh)
*
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
JP2012530704A
(ja)
|
2009-06-18 |
2012-12-06 |
アボット・ラボラトリーズ |
安定なナノ粒子状薬物懸濁液
|
NZ598083A
(en)
*
|
2009-08-24 |
2013-08-30 |
Lundbeck & Co As H |
New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
|
RU2551376C2
(ru)
*
|
2009-09-20 |
2015-05-20 |
Эббви Инк. |
Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2
|
SG10201500152UA
(en)
*
|
2009-12-22 |
2015-03-30 |
Abbvie Inc |
Abt-263 capsule
|
US8710035B2
(en)
|
2010-03-24 |
2014-04-29 |
The University Of Chicago |
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
|
AU2014202478B2
(en)
*
|
2010-03-25 |
2016-04-28 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
MX2012011086A
(es)
*
|
2010-03-25 |
2013-03-21 |
Abbvie Inc |
Agentes inductores de apoptosis para el tratamiento de cancer y de enfermedades inmunitarias y autoinmunitarias.
|
CN101798292A
(zh)
*
|
2010-03-29 |
2010-08-11 |
无锡好芳德药业有限公司 |
ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
|
TWI520960B
(zh)
|
2010-05-26 |
2016-02-11 |
艾伯維有限公司 |
用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
|
NZ789041A
(en)
|
2010-06-03 |
2023-09-29 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
TWI535712B
(zh)
*
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
SG10201801794WA
(en)
|
2010-10-29 |
2018-04-27 |
Abbvie Inc |
Solid dispersions containing an apoptosis-inducing agent
|
LT2643322T
(lt)
|
2010-11-23 |
2018-01-10 |
Abbvie Inc. |
Apoptozę skatinančio agento druskos ir kristalinės formos
|
UA119150C2
(uk)
|
2010-11-23 |
2019-05-10 |
Еббві Айрленд Анлімітед Компані |
СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2
|
AU2012209295B2
(en)
|
2011-01-25 |
2016-06-30 |
The Regents Of The University Of Michigan |
Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
|
EP2672969A4
(en)
*
|
2011-02-01 |
2014-07-16 |
Glaxosmithkline Intellectual Property Ltd |
ASSOCIATION
|
US20140189897A1
(en)
|
2011-06-21 |
2014-07-03 |
Mayo Foundation For Medical Education And Research |
Transgenic animals capable of being induced to delete senescent cells
|
WO2013053045A1
(en)
|
2011-10-12 |
2013-04-18 |
Beta Pharma Canada Inc. |
Heterocyclic molecules as apoptosis inducers
|
CN103127510B
(zh)
*
|
2011-11-30 |
2015-03-25 |
北京天和瑞通科技发展有限公司 |
含有肝细胞生长因子受体抑制剂和Bcl-2抑制剂的药物组合物及其应用
|
RU2014128010A
(ru)
|
2011-12-13 |
2016-02-10 |
Бак Инститьют Фо Рисерч Он Эйджин |
Способы улучшения средств консервативной терапии
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
WO2013158664A2
(en)
|
2012-04-17 |
2013-10-24 |
Kythera Biopharmaceuticals, Inc. |
Use of engineered viruses to specifically kill senescent cells
|
US8859774B2
(en)
|
2012-05-25 |
2014-10-14 |
Corcept Therapeutics, Inc. |
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
|
US9901080B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
|
US9901081B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse for determining the role of senescent cells in cancer
|
US9096625B2
(en)
|
2013-01-16 |
2015-08-04 |
The Regents Of The University Of Michigan |
BCL-2/BCL-XL inhibitors and therapeutic methods using the same
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
US20140279528A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Motorola Mobility Llc |
Wearable Authentication Device
|
ES2822285T3
(es)
|
2013-07-30 |
2021-04-30 |
Kronos Bio Inc |
Polimorfo de inhibidores de SYK
|
US10071130B2
(en)
|
2013-12-12 |
2018-09-11 |
The University Of Chicago |
Methods and compositions related to Hsp90 inhibitors and breast cancer
|
TWI662037B
(zh)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
脾酪胺酸激酶抑制劑
|
CA3100140C
(en)
|
2014-01-28 |
2023-10-24 |
Buck Institute For Research On Aging |
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
|
WO2015116735A1
(en)
|
2014-01-28 |
2015-08-06 |
Mayo Foundation For Medical Education And Research |
Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
MA40075A
(fr)
|
2014-07-14 |
2016-01-21 |
Gilead Sciences Inc |
Combinaisons pour traiter des cancers
|
CN117088931A
(zh)
|
2014-08-12 |
2023-11-21 |
莫纳什大学 |
定向淋巴的前药
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
WO2016131100A1
(en)
*
|
2015-02-18 |
2016-08-25 |
The Walter And Eliza Hall Institute Of Medical Research |
Methods of treating infectious diseases
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
US10195213B2
(en)
|
2015-03-13 |
2019-02-05 |
Unity Biotechnology, Inc. |
Chemical entities that kill senescent cells for use in treating age-related disease
|
EP3331546B1
(en)
|
2015-08-03 |
2023-10-04 |
Biokine Therapeutics Ltd. |
Cxcr4 inhibitor for the treatment of cancer
|
US10023571B2
(en)
|
2015-09-02 |
2018-07-17 |
Nimbus Lakshimi, Inc. |
TYK2 inhibitors and uses thereof
|
CN118063537A
(zh)
|
2015-09-08 |
2024-05-24 |
莫纳什大学 |
定向淋巴的前药
|
WO2017044720A1
(en)
|
2015-09-11 |
2017-03-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
PT3364958T
(pt)
|
2015-10-23 |
2023-04-10 |
Navitor Pharm Inc |
Moduladores de interação sestrina-gator2 e utilizações dos mesmos
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
US11111259B2
(en)
|
2015-12-18 |
2021-09-07 |
Unity Biotechnology, Inc. |
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
|
EP3936153A1
(en)
|
2016-01-11 |
2022-01-12 |
Celator Pharmaceuticals, Inc. |
Inhibiting ataxia telangiectasia and rad3-related protein (atr)
|
WO2017123616A1
(en)
*
|
2016-01-11 |
2017-07-20 |
Merrimack Pharmaceuticals, Inc. |
Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
|
WO2017156179A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
ES2965264T3
(es)
|
2016-03-09 |
2024-04-11 |
Raze Therapeutics Inc |
Inhibidores de la 3-fosfoglicerato deshidrogenasa y sus usos
|
IL261721B
(en)
|
2016-03-15 |
2022-07-01 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
MY197785A
(en)
|
2016-03-15 |
2023-07-13 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
JP7114478B2
(ja)
|
2016-03-28 |
2022-08-08 |
プレサージュ バイオサイエンシズ,インコーポレイテッド |
癌の治療のための配合剤
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
US10807977B2
(en)
|
2016-04-21 |
2020-10-20 |
Bioventures, Llc |
Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
|
WO2017223229A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
CA3027498A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
CN110300590A
(zh)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
US20180133212A1
(en)
|
2016-11-03 |
2018-05-17 |
Gilead Sciences, Inc. |
Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
CN110177544A
(zh)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
用于递送治疗剂的外泌体
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
CA3055209A1
(en)
|
2017-03-08 |
2018-09-13 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
KR102342620B1
(ko)
|
2017-03-31 |
2021-12-22 |
코어셉트 쎄라퓨틱스 인코포레이티드 |
자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
CN116370448A
(zh)
|
2017-04-26 |
2023-07-04 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂及其用途
|
MX2020001103A
(es)
|
2017-07-28 |
2020-08-17 |
Nimbus Lakshmi Inc |
Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
|
KR102399996B1
(ko)
|
2017-08-25 |
2022-05-20 |
길리애드 사이언시즈, 인코포레이티드 |
Syk 억제제의 다형체
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
AU2018338314A1
(en)
|
2017-09-22 |
2020-04-09 |
Kymera Therapeutics, Inc |
Protein degraders and uses thereof
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
JP2021508703A
(ja)
|
2017-12-26 |
2021-03-11 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
MX2020007392A
(es)
|
2018-01-10 |
2020-10-14 |
Recurium Ip Holdings Llc |
Compuestos de benzamida.
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND THEIR USES
|
US10988477B2
(en)
|
2018-01-29 |
2021-04-27 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Gcn2阻害剤およびその使用
|
US10696663B2
(en)
|
2018-02-27 |
2020-06-30 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of TCR-NCK interaction
|
WO2019178433A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
|
MX2020011089A
(es)
|
2018-04-24 |
2020-11-06 |
Merck Patent Gmbh |
Compuestos antiproliferacion y usos de los mismos.
|
AU2019257651B2
(en)
|
2018-04-24 |
2023-05-25 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
KR20210005677A
(ko)
|
2018-04-29 |
2021-01-14 |
베이진 엘티디 |
Bcl-2 억제제
|
CA3103282A1
(en)
|
2018-06-15 |
2019-12-19 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
US11491168B2
(en)
|
2018-07-31 |
2022-11-08 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2020061216A1
(en)
|
2018-09-18 |
2020-03-26 |
Signalchem Lifesciences Corporation |
Combination therapy for treating blood cancer
|
AU2019360941A1
(en)
|
2018-10-15 |
2021-04-29 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US11345654B2
(en)
|
2018-10-24 |
2022-05-31 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2022509260A
(ja)
|
2018-11-30 |
2022-01-20 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
US11234971B2
(en)
|
2018-12-19 |
2022-02-01 |
Corcept Therapeutics Incorporated |
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
|
WO2020132046A1
(en)
|
2018-12-19 |
2020-06-25 |
Corcept Therapeutics Incorporated |
Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
|
CN113194931B
(zh)
|
2018-12-19 |
2023-11-10 |
科塞普特治疗公司 |
含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CN113348021A
(zh)
|
2019-01-23 |
2021-09-03 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
KR20210131372A
(ko)
|
2019-02-22 |
2021-11-02 |
크로노스 바이오, 인코포레이티드 |
Syk 억제제로서의 축합된 피라진의 고체 형태
|
JP2022523376A
(ja)
|
2019-02-22 |
2022-04-22 |
コーセプト セラピューティクス, インコーポレイテッド |
レラコリラント、ヘテロアリール-ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
TW202106676A
(zh)
|
2019-04-05 |
2021-02-16 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
EP3983006A1
(en)
|
2019-06-12 |
2022-04-20 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
IL292612A
(en)
|
2019-11-01 |
2022-07-01 |
Navitor Pharm Inc |
Treatment methods using mtorc1 modulator
|
KR20220098755A
(ko)
|
2019-11-05 |
2022-07-12 |
애브비 인코포레이티드 |
나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘
|
IL293549A
(en)
|
2019-12-05 |
2022-08-01 |
Anakuria Therapeutics Inc |
Rapamycin analogs and their uses
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
EP4081308A4
(en)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics Inc |
SMARCA DEGRADERS AND USES THEREOF
|
KR20220149534A
(ko)
|
2020-02-05 |
2022-11-08 |
퓨어테크 엘와이티, 아이엔씨. |
신경스테로이드의 지질 전구약물
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
CN115776887A
(zh)
|
2020-03-19 |
2023-03-10 |
凯麦拉医疗公司 |
Mdm2降解剂和其用途
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
WO2022008464A1
(en)
|
2020-07-06 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
IL300175A
(en)
|
2020-07-30 |
2023-03-01 |
Kymera Therapeutics Inc |
Methods for treating mutant lymphomas
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
CN117098757A
(zh)
|
2021-02-02 |
2023-11-21 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
CN118103368A
(zh)
|
2021-08-25 |
2024-05-28 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
GB202201824D0
(en)
|
2022-02-11 |
2022-03-30 |
Genome Res Ltd |
Methods of treatment
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023215449A1
(en)
|
2022-05-06 |
2023-11-09 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
TW202400589A
(zh)
|
2022-05-06 |
2024-01-01 |
美商樹線生物科學公司 |
四氫異喹啉異雙功能bcl—xl降解劑
|
WO2023215471A1
(en)
|
2022-05-06 |
2023-11-09 |
Treeline Biosciences, Inc. |
Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2024012557A1
(en)
*
|
2022-07-15 |
2024-01-18 |
Berrybio (Hong Kong) Limited |
Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|